{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:23Z","timestamp":1794047483020,"version":"4.8.0"},"reference-count":46,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"3","license":[{"start":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T00:00:00Z","timestamp":1730332800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Blinatumomab has remarkable efficacy in patients with relapsed\/refractory (r\/r) or measurable residual disease (MRD)-positive B-cell acute lymphoblastic leukemia (B-ALL). In many patients, blinatumomab treatment is followed by allogeneic hematopoietic stem cell transplantation (HSCT). However, the influence of blinatumomab on HSCT outcomes in children and young adults (YA) remains to be fully elucidated. We conducted a single-center, retrospective analysis of patients given blinatumomab as last treatment before HSCT. Seventy-eight pediatric and YA patients were evaluated. With a median follow- up of 23.23 months, the 2-year disease-free (DFS) and overall survival (OS) probability were 72.2% and 89.2%, respectively, with a 2-year cumulative incidence of non-relapse mortality (NRM) of 2.6%. A trend toward improved 2-year DFS, but not OS, was noted in patients transplanted in first complete remission (CR1) (92.9%) compared to those in second or greater remission (CR2\/3) (68.5%; P=0.18) due to a lower cumulative incidence of relapse (0% vs. 29.9%; P=0.05). Among CR2\/3 patients, those receiving the sequential combination of inotuzumab and blinatumomab had a significantly lower cumulative incidence of relapse as compared to those who did not receive inotuzumab (9.5% vs. 40.4%; P=0.023). Relapse after HSCT occurred in 16 patients, all exhibiting CD19-positive blasts; ten of them received anti-CD19 chimeric antigen receptor T-cell (CAR T) therapy and two inotuzumab as salvage therapy, leading to a 2-year post-relapse OS of 52.7%. Our results indicate that HSCT following blinatumomab in children and YA with B-ALL is highly effective, being associated with low NRM and not affecting the efficacy of subsequent salvage immunotherapies, including CAR T cells.<\/jats:p>","DOI":"10.3324\/haematol.2024.286350","type":"journal-article","created":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T04:10:17Z","timestamp":1730347817000},"page":"596-607","source":"Crossref","is-referenced-by-count":9,"title":["Outcomes of children and young adults with B-cell acute lymphoblastic leukemia given blinatumomab as last consolidation treatment before allogeneic hematopoietic stem cell transplantation"],"prefix":"10.3324","volume":"110","author":[{"given":"Mattia","family":"Algeri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Massa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daria","family":"Pagliara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Bertaina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Galaverna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Pili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"Li Pira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Carta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Quagliarella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita M.","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Rosignoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbarella","family":"Lucarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria G.","family":"Cefalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia","family":"Boccieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Benini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Del Bufalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Becilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Merli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Zugmaier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Locatelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,10,31]]},"reference":[{"key":"72966","doi-asserted-by":"crossref","unstructured":"Pierro J, Hogan LE, Bhatla T, Carroll WL. New targeted therapies for relapsed pediatric acute lymphoblastic leukemia. Expert Rev Anticancer Ther. 2017; 17(8):725-736.","DOI":"10.1080\/14737140.2017.1347507"},{"key":"72967","doi-asserted-by":"crossref","unstructured":"Lovisa F, Zecca M, Rossi B. Pre- and post-transplant minimal residual disease predicts relapse occurrence in children with acute lymphoblastic leukaemia. Br J Haematol. 2018; 180(5):680-693.","DOI":"10.1111\/bjh.15086"},{"key":"72968","doi-asserted-by":"crossref","unstructured":"Bader P, Salzmann-Manrique E, Balduzzi A. More precisely defining risk peri-HCT in pediatric ALL: pre- vs post-MRD measures, serial positivity, and risk modeling. Blood Adv. 2019; 3(21):3393-3405.","DOI":"10.1182\/bloodadvances.2019000449"},{"key":"72969","doi-asserted-by":"crossref","unstructured":"Lyons KU, Gore L. Bispecific T-cell engagers in childhood B-acute lymphoblastic leukemia. Haematologica. 2024; 109(6):1668-1676.","DOI":"10.3324\/haematol.2023.283818"},{"key":"72970","doi-asserted-by":"crossref","unstructured":"Algeri M, Del Bufalo F, Galaverna F, Locatelli F. Current and future role of bispecific T-cell engagers in pediatric acute lymphoblastic leukemia. Expert Rev Hematol. 2018; 11(12):945-956.","DOI":"10.1080\/17474086.2018.1540928"},{"key":"72971","doi-asserted-by":"crossref","unstructured":"von Stackelberg A, Locatelli F, Zugmaier G. Phase I\/phase II study of blinatumomab in pediatric patients with relapsed\/ refractory acute lymphoblastic leukemia. J Clin Oncol. 2016; 34(36):4381-4389.","DOI":"10.1200\/JCO.2016.67.3301"},{"key":"72972","doi-asserted-by":"crossref","unstructured":"G\u00f6kbuget N, Dombret H, Bonifacio M. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood. 2018; 131(14):1522-1531.","DOI":"10.1182\/blood-2017-08-798322"},{"key":"72973","doi-asserted-by":"crossref","unstructured":"Kantarjian H, Stein A, G\u00f6kbuget N. Blinatumomab versus chemotherapy for advanced Acute lymphoblastic leukemia. N Engl J Med. 2017; 376(9):836-847.","DOI":"10.1056\/NEJMoa1609783"},{"key":"72974","doi-asserted-by":"crossref","unstructured":"Locatelli F, Zugmaier G, Rizzari C. Effect of blinatumomab vs chemotherapy on event-free survival among children with high-risk first-relapse B-cell acute lymphoblastic leukemia: a randomized clinical trial. JAMA. 2021; 325(9):843-854.","DOI":"10.1001\/jama.2021.0987"},{"key":"72975","doi-asserted-by":"crossref","unstructured":"Brown PA, Ji L, Xu X. Effect of postreinduction therapy consolidation with blinatumomab vs chemotherapy on disease-free survival in children, adolescents, and young adults with first relapse of B-cell acute lymphoblastic leukemia: a randomized clinical trial. JAMA. 2021; 325(9):833-842.","DOI":"10.1001\/jama.2021.0669"},{"key":"72976","doi-asserted-by":"crossref","unstructured":"Locatelli F, Eckert C, Hrusak O. Blinatumomab overcomes poor prognostic impact of measurable residual disease in pediatric high\u2010risk first relapse B\u2010cell precursor acute lymphoblastic leukemia. Pediatr Blood Cancer. 2022; 69(8):e29715.","DOI":"10.1002\/pbc.29715"},{"key":"72977","doi-asserted-by":"crossref","unstructured":"Locatelli F, Zugmaier G, Rizzari C. Improved survival and MRD remission with blinatumomab vs. chemotherapy in children with first high-risk relapse B-ALL. Leukemia. 2023; 37(1):222-225.","DOI":"10.1038\/s41375-022-01770-3"},{"key":"72978","doi-asserted-by":"crossref","unstructured":"Hogan LE, Brown PA, Ji L. Children\u2019s Oncology Group AALL1331: phase III trial of blinatumomab in children, adolescents, and young adults with low-risk B-cell ALL in first relapse. J Clin Oncol. 2023; 41(25):4118-4129.","DOI":"10.1200\/JCO.22.02200"},{"key":"72979","doi-asserted-by":"crossref","unstructured":"Locatelli F, Zugmaier G, Mergen N. Blinatumomab in pediatric relapsed\/refractory B-cell acute lymphoblastic leukemia: RIALTO expanded access study final analysis. Blood Adv. 2022; 6(3):1004-1014.","DOI":"10.1182\/bloodadvances.2021005579"},{"key":"72980","doi-asserted-by":"crossref","unstructured":"Algeri M, Merli P, Locatelli F, Pagliara D. The role of allogeneic hematopoietic stem cell transplantation in pediatric leukemia. J Clin Med. 2021; 10(17):3790.","DOI":"10.3390\/jcm10173790"},{"key":"72981","doi-asserted-by":"crossref","unstructured":"Harris AC, Young R, Devine S. International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai Acute GVHD International Consortium. Biol Blood Marrow Transplant. 2016; 22(1):4-10.","DOI":"10.1016\/j.bbmt.2015.09.001"},{"key":"72982","doi-asserted-by":"crossref","unstructured":"Jagasia MH, Greinix HT, Arora M. National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant. 2015; 21(3):389-401.","DOI":"10.1016\/j.bbmt.2014.12.001"},{"key":"72983","doi-asserted-by":"crossref","unstructured":"Locatelli F, Bernardo ME, Bertaina A. Efficacy of two different doses of rabbit anti-T-lymphocyte globulin to prevent graft-versus-host disease in children with haematological malignancies transplanted from an unrelated donor: a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2017; 18(8):1126-1136.","DOI":"10.1016\/S1470-2045(17)30417-5"},{"key":"72984","doi-asserted-by":"crossref","unstructured":"Merli P, Algeri M, Galaverna F. TCR\u03b1\u03b2\/CD19 cell\u2013depleted HLA-haploidentical transplantation to treat pediatric acute leukemia: updated final analysis. Blood. 2024; 143(3):279-289.","DOI":"10.1182\/blood.2023021336"},{"key":"72985","doi-asserted-by":"crossref","unstructured":"Sutton R, Shaw PJ, Venn NC. Persistent MRD before and after allogeneic BMT predicts relapse in children with acute lymphoblastic leukaemia. Br J Haematol. 2015; 168(3):395-404.","DOI":"10.1111\/bjh.13142"},{"key":"72986","doi-asserted-by":"crossref","unstructured":"Berry DA, Zhou S, Higley H. Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis. JAMA Oncol. 2017; 3(7):e170580.","DOI":"10.1001\/jamaoncol.2017.0580"},{"key":"72987","doi-asserted-by":"crossref","unstructured":"Balduzzi A, Dalle J-H, Wachowiak J. Transplantation in children and adolescents with acute lymphoblastic leukemia from a matched donor versus an HLA-identical sibling: is the outcome comparable? Results from the International BFM ALL SCT 2007 Study. Biol Blood Marrow Transplant. 2019; 25(11):2197-2210.","DOI":"10.1016\/j.bbmt.2019.07.011"},{"key":"72988","doi-asserted-by":"crossref","unstructured":"Peters C, Schrappe M, Von Stackelberg A. Stem-cell transplantation in children with acute lymphoblastic leukemia: a prospective international multicenter trial comparing sibling donors with matched unrelated donors - the ALL-SCT-BFM-2003 trial. J Clin Oncol. 2015; 33(11):1265-1274.","DOI":"10.1200\/JCO.2014.58.9747"},{"key":"72989","doi-asserted-by":"crossref","unstructured":"Peters C, Dalle J-H, Locatelli F. Total body irradiation or chemotherapy conditioning in childhood ALL: a multinational, randomized, noninferiority phase III study. J Clin Oncol. 2021; 39(4):295-307.","DOI":"10.1200\/JCO.20.02529"},{"key":"72990","doi-asserted-by":"crossref","unstructured":"Leahy AB, Devine KJ, Li Y. Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CAR T-cell therapy. Blood. 2022; 139(14):2173-2185.","DOI":"10.1182\/blood.2021012727"},{"key":"72991","doi-asserted-by":"crossref","unstructured":"Hof J, Krentz S, van Schewick C. Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia. J Clin Oncol. 2011; 29(23):3185-3193.","DOI":"10.1200\/JCO.2011.34.8144"},{"key":"72992","doi-asserted-by":"crossref","unstructured":"Pan J, Tan Y, Deng B. Frequent occurrence of CD19-negative relapse after CD19 CAR T and consolidation therapy in 14 TP53-mutated r\/r B-ALL children. Leukemia. 2020; 34(12):3382-3387.","DOI":"10.1038\/s41375-020-0831-z"},{"key":"72993","doi-asserted-by":"crossref","unstructured":"Calvo C, Ronceray L, Dh\u00e9din N, Buechner J, Troeger A, Dalle J-H. Haematopoietic stem cell transplantation in adolescents and young adults with acute lymphoblastic leukaemia: special considerations and challenges. Front Pediatr. 2022; 9:796426.","DOI":"10.3389\/fped.2021.796426"},{"key":"72994","doi-asserted-by":"crossref","unstructured":"Fo\u00e0 R, Chiaretti S. Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med. 2022; 386(25):2399-2411.","DOI":"10.1056\/NEJMra2113347"},{"key":"72995","doi-asserted-by":"crossref","unstructured":"Sayyed A, Chen C, Gerbitz A. Pretransplant blinatumomab improves outcomes in B cell acute lymphoblastic leukemia patients who undergo allogeneic hematopoietic cell transplantation. Transplant Cell Ther. 2024; 30(5):520.e1-520.e12.","DOI":"10.1016\/j.jtct.2024.03.004"},{"key":"72996","doi-asserted-by":"crossref","unstructured":"Llaurador G, Shaver K, Wu M. Blinatumomab therapy is associated with favorable outcomes after allogeneic hematopoietic cell transplantation in pediatric patients with B cell acute lymphoblastic leukemia. Transplant Cell Ther. 2024; 30(2):217-227.","DOI":"10.1016\/j.jtct.2023.10.024"},{"key":"72997","doi-asserted-by":"crossref","unstructured":"Bhojwani D, Sposto R, Shah NN. Inotuzumab ozogamicin in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia. Leukemia. 2019; 33(4):884-892.","DOI":"10.1038\/s41375-018-0265-z"},{"key":"72998","doi-asserted-by":"crossref","unstructured":"O\u2019Brien MM, Ji L, Shah NN. Phase II trial of inotuzumab ozogamicin in children and adolescents with relapsed or refractory B-cell acute lymphoblastic leukemia: Children\u2019s Oncology Group Protocol AALL1621. J Clin Oncol. 2022; 40(9):956-967.","DOI":"10.1200\/JCO.21.01693"},{"key":"72999","doi-asserted-by":"crossref","unstructured":"Pennesi E, Michels N, Brivio E. Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial. Leukemia. 2022; 36(6):1516-1524.","DOI":"10.1038\/s41375-022-01576-3"},{"key":"73000","doi-asserted-by":"crossref","unstructured":"Badar T, Szabo A, Litzow M. Multi-institutional study evaluating clinical outcome with allogeneic hematopoietic stem cell transplantation after blinatumomab in patients with B-cell acute lymphoblastic leukemia: real-world data. Bone Marrow Transplant. 2021; 56(8):1998-2004.","DOI":"10.1038\/s41409-021-01279-w"},{"key":"73001","doi-asserted-by":"crossref","unstructured":"Nam M, Hur M, Kim H. Clinical impact of recipient-derived isoagglutinin levels in ABO-incompatible hematopoietic stem cell transplantation. J Clin Med. 2023; 12(2):458.","DOI":"10.3390\/jcm12020458"},{"key":"73002","doi-asserted-by":"crossref","unstructured":"Jarisch A, Salzmann-Manrique E, Soerensen J. Donor-type red blood cell transfusion to deplete isoagglutinins prior to allogeneic stem cell transplantation from ABO major incompatible bone marrow donors. Br J Haematol. 2023; 201(6):1159-1168.","DOI":"10.1111\/bjh.18761"},{"key":"73003","doi-asserted-by":"crossref","unstructured":"Ataca Atilla P, Akkus E, Atilla E. Effects of ABO incompatibility in allogeneic hematopoietic stem cell transplantation. Transfus Clin Biol. 2020; 27(3):115-121.","DOI":"10.1016\/j.tracli.2020.06.008"},{"key":"73004","doi-asserted-by":"crossref","unstructured":"Booth GS, Gehrie EA, Bolan CD, Savani BN. Clinical guide to ABO-incompatible allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2013; 19(8):1152-1158.","DOI":"10.1016\/j.bbmt.2013.03.018"},{"key":"73005","doi-asserted-by":"crossref","unstructured":"Migdady Y, Pang Y, Kalsi SS, Childs R, Arai S. Post-hematopoietic stem cell transplantation immune-mediated anemia: a literature review and novel therapeutics. Blood Adv. 2022; 6(8):2707-2721.","DOI":"10.1182\/bloodadvances.2021006279"},{"key":"73006","doi-asserted-by":"crossref","unstructured":"Maude SL, Laetsch TW, Buechner J. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018; 378(5):439-448.","DOI":"10.1056\/NEJMoa1709866"},{"key":"73007","doi-asserted-by":"crossref","unstructured":"Myers RM, Shah NN, Pulsipher MA. How I use risk factors for success or failure of CD19 CAR T cells to guide management of children and AYA with B-cell ALL. Blood. 2023; 141(11):1251-1264.","DOI":"10.1182\/blood.2022016937"},{"key":"73008","doi-asserted-by":"crossref","unstructured":"Myers RM, Taraseviciute A, Steinberg SM. Blinatumomab nonresponse and high-disease burden are associated with inferior outcomes after CD19-CAR for B-ALL. J Clin Oncol. 2022; 40(9):932-944.","DOI":"10.1200\/JCO.21.01405"},{"key":"73009","doi-asserted-by":"crossref","unstructured":"Laetsch TW, Maude SL, Rives S. Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia in the ELIANA Trial. J Clin Oncol. 2023; 41(9):1664-1669.","DOI":"10.1200\/JCO.22.00642"},{"key":"73010","doi-asserted-by":"crossref","unstructured":"Bader P, Rossig C, Hutter M. CD19 CAR T cells are an effective therapy for posttransplant relapse in patients with B-lineage ALL: real-world data from Germany. Blood Adv. 2023; 7(11):2436-2448.","DOI":"10.1182\/bloodadvances.2022008981"},{"key":"73011","doi-asserted-by":"crossref","unstructured":"Del Bufalo F, Becilli M, Rosignoli C. Allogeneic, donor-derived, second-generation, CD19-CAR-T cell for the treatment of pediatric relapsed\/refractory BCP-ALL. Blood. 2023; 142(2):146-157.","DOI":"10.1182\/blood.2023020023"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2024.286350\/77737","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2024.286350\/78095","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11811\/77737","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:07:31Z","timestamp":1794046051000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2024.286350"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,31]]},"references-count":46,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2024.286350","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,31]]}}}